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July 18, 2006:411–20arrow cells—in both acute and chronic infarction—represents a
nique chance for the compromised heart muscle because all of the
hree bone marrow cell fractions (CD34 positive, CD34 negative,
D133 angioblasts) contribute to its myocardial regeneration.
hus, the speculative assumption of apoptotic-induced cell mod-
lation, which may be discussed for acutely infarcted myocardium,
s neither conclusive nor necessary in chronic coronary disease. All
ur chronic patients (n  36) (the IACT study) fulfilled the same
nclusion criteria (e.g., randomization; equal procedural cardiac
atheterization techniques; standardized cell isolation and harvest-
ng) (2,3).
Moreover, both the intracoronary cell delivery via balloon
atheter and the production of enhanced environment by balloon-
nduced ischemia during the course of intracoronary cell transplan-
ation were the same. The identity and number of bone marrow
tem cells transplanted were exactly quantified for each patient
2,3), and the exact quantification of regional ventricular function
nd contractility has been extensively validated in our clinic (4).
As to our actual knowledge, the regenerative potential of
ononuclear bone marrow cells refers at least to four different
echanisms: direct cell transdifferentiation, cytokine-mediated
timulation of nondestroyed myocytes, mobilization of intrinsic
tem cells, and cell fusion. The high (four-fold) mitotic potency of
order zone myocardium (5) suggests that several of these four
echanisms together may play a role.
Finally, what remains clear is that intracoronary stem cell
ransplantation, as has been described by our original report (1), is
n exclusive procedure for regenerating acutely and/or chronically
ompromised myocardium. We agree that it is desirable that larger
linical trials, as in acute infarction, may also confirm these
eneficial data for chronic coronary heart disease.
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ost Advantage of Different
ardioverter-Defibrillator Devices
mong patients without a bradycardia indication for pacing, the
resumed benefits of routine dual- versus single-chamber implant-
ble cardioverter-defibrillator (ICD) usage, including a potential
eduction in inappropriate shocks by enhancement of supraven-
ricular tachycardia detection, remain unproven (1). Adding to the
ist of soft reasons for routine dual-chamber device usage is the
ecent study in JACC by Goldberger et al. (2), who analyzed the
nancial costs associated with a strategy of universal dual-chamber
CD placement versus implantation of a single-chamber ICD
ollowed by upgrade as clinically indicated. That analysis suggests
hat even with upgrade rates as low as 5%, a universal dual-
hamber implant approach could be the most cost-effective.
owever, the analysis could not consider two costs, which, though
ot monetary, are of primary importance.
First, the addition of implanting an atrial lead is associated, not
urprisingly, with at least a doubling of device and lead-related
omplication rates (3–5). This price would be paid by our patients
irectly should a universal dual-chamber implant approach be
aken.
Second, there would be an unmeasurable price paid by our
rofession as a whole were we to abandon our ethical obligation to
ur individual patients by employing a strategy that asks them to
houlder the burden of unnecessary medical procedures in the
nterests of reducing “costs to the system.” Surgeons accept
erforming 1 or 2 unnecessary appendectomies in 10 to minimize
he chance of perforated appendicitis (6). Are we to accept
erforming more than 9 unnecessary procedures in 10 and placing
ore than 90% of our patients in (unnecessary) harm’s way to save
ome money? The clinical benefits that we might realistically
xpect our individual patients to experience from a universal dual-
ersus single-chamber implantation approach must first be estab-
ished before any cost analysis such as this one should have any
nfluence on ethical practice.
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EPLY
r. Veenhuyzen argues that inserting dual-chamber implantable
ardioverter-defibrillators (ICDs) in the interest of cost-saving is
nethical, because those patients who would not go on to require
n upgrade are asked to “shoulder the burden of unnecessary
edical procedures” by having the dual-chamber device implanted
pfront. This argument rests on the assumption that the risks of
trial lead implantation outweigh the benefits of the dual-chamber
evice. However, the benefits are likely greater than outlined in
r. Veenhuyzen’s letter.
As described and referenced in our study (1), although not all
tudies show improved discrimination between ventricular and
upraventricular arrhythmias with the dual-chamber device, most
o. Further, even if there were no benefit, the issue of risk is more
omplicated than that described. There is an increased risk of atrial
ead dislodgement with the dual-chamber device (other complica-
ions are not different). However, as referenced in our study, there
s also an increased risk of infection, a more serious complication,
ith upgrade. Even if there were no benefit at all, patients might
rade an upfront risk of a less-serious complication to avoid the
ossibility of a more serious risk later on. Thus, we believe that our
ata show not that a strategy of universal dual-chamber ICD
lacement would trade clinical good for cost-saving, but rather that
he most beneficial approach for the patient is also the least
xpensive for the health care system.
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oppler Echocardiographic Profile and Indexes
e read with interest the study published recently in the Journal
y Tan et al. (1). We have several concerns.
First, the investigators point out in the Limitations section thathe modified Bernoulli equation was not used in their study. bowever, Tan and colleagues do not give a justifiable reason for
his in the cases studied. Did all these patients have a pre-
oarctation velocity (i.e., V1) that was1 m/s? Our concern is that
his approach may mislead clinicians. Giving only a brief passing
ention for the necessity for the modified Bernoulli equation in
he Limitations section is troubling andmay lead to misconceptions in
he way this lesion is assessed in the cardiology community.
Second, and more important, the researchers mention that the
eak systolic pressure gradient (SPG) is dependent on aortic
ompliance, and they reference a study by Tacy et al. (2). However,
here is no mention that the measurement they propose clinicians
se (diastolic velocity [DV]) may also be related to compliance as
ell. Experiments performed by Tacy et al. (2) and in our
aboratory (3) suggest that diastolic runoff, and thus DV, depend
n vessel compliance. To understand this point one simply has to
ake the argument to the extremes. If the entire aorta is noncom-
liant then there can be no diastolic runoff, even considering the
ost severe coarctation lesion. Of course, such a condition for the
ntire aorta is unlikely to exist, but it is useful to consider to
emonstrate the concept of the relationship between diastolic
unoff and aortic compliance. Taking several steps back from this
xtreme, if one considers the complexities to flow that occur with
stiff stent in place after intervention, it is clear that significantly
ore investigations are needed before such parameters as DV are
reely used in clinical practice.
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EPLY
he comment given in the Limitations section of our study (1)
egarding the modified Bernoulli equation was aimed at highlight-
ng the fact that the equation should not be used for low velocities
wing to mathematical properties of the exponential curves.
If we make the simple assumption that the flow through the
oarctation is dominated by resistance, then the flow is determined
y that resistance and the pressure difference across it. Thus,
